NCT05294731 2026-04-17
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
BeOne Medicines
Phase 1/2 Recruiting
BeOne Medicines
BeOne Medicines
ModeX Therapeutics, An OPKO Health Company